Business / Finance

RSS

Orthofix net sales reduce 10% to $106.1M in fourth quarter 2013

Orthofix International N.V., today reported results for the fourth quarter and full year ended Dec. 31, 2013. For full-year 2013, net sales were $400.5 million, decreasing 11 percent on a reported basis and constant currency basis from $447.6 million in the prior year.

27 Mar 2014

ChromaDex declares full-year 2013 financial results

ChromaDex® Corp., an innovative natural products company that provides proprietary, ingredients and science-based solutions to the dietary supplement, food and beverage, animal health, cosmetic and pharmaceutical industries, announced today the financial results for the year ended December 28, 2013.

27 Mar 2014

Personalis and Inova team up to advance genomic medicine

Inova Translational Medicine Institute and Personalis, Inc. today announced a partnership to advance genomic medicine for Inova's patient population.

27 Mar 2014

Egalet provides business update, reports full year 2013 financial results

Egalet Corporation ("Egalet") today reported business highlights and financial results for the year ended December 31, 2013. This marks the first time that Egalet is reporting its operating results as a public company.

26 Mar 2014

Deerfield signs agreement to provide Wellfount with $15 million in funding

Deerfield Management Company announced today that it has entered into an agreement to provide Wellfount Corporation with $15.0 million in funding. With these amounts, Wellfount will possess sufficient working capital to continue to expand the portfolio of long term care facilities in which its innovative pharmacy solution is implemented.

26 Mar 2014

Mast Therapeutics reports net loss of $5.7 million for fourth quarter 2013

Mast Therapeutics, Inc. today reported financial results for the fourth quarter and year ended December 31, 2013.

26 Mar 2014

New international partnership aims to increase wheat yields by 50% by 2034

A new international partnership aims to increase wheat yields by 50 percent by 2034. This will address demand for wheat - one of the world's most important crops - that is growing much faster than production.

26 Mar 2014

Hooper Holmes reports 1% decline in consolidated revenues for Q4 2013

Hooper Holmes, Inc. today announced financial results for the year ended December 31, 2013.

26 Mar 2014

Xenon collaborates with Genentech to develop new therapeutic targets for treating pain

Xenon Pharmaceuticals Inc. today announced the establishment of a new collaboration with Genentech, a member of the Roche Group, for pain genetics, with the goal of discovering and validating new therapeutic targets and mechanisms for treating pain.

26 Mar 2014

Axonics Modulation Technologies completes $32.6 million Series A preferred stock financing

Axonics Modulation Technologies, Inc., a developer of novel implantable neuromodulation technology, announced today that it has completed a $32.6 million Series A preferred stock financing.

25 Mar 2014

Singulex signs agreement to co-develop the Sgx Clarity system with Tecan

Singulex, Inc., the developer and leading provider of Single Molecule Counting (SMC) technology for clinical diagnostics and scientific discovery, today announced an agreement to co-develop the Sgx Clarity system with Tecan, a leading global provider of laboratory automation instruments.

From Tecan 25 Mar 2014

North Coast Medical announces acquisition of ActivaTek

North Coast Medical, Inc., a manufacturer and global supplier of physical rehabilitation medical products, today announced the acquisition of Salt Lake City, Utah-based ActivaTek, Inc., a privately held manufacturer of transdermal iontophoretic devices.

25 Mar 2014

BioRestorative Therapies, Rohto sign Research and Development Agreement

BioRestorative Therapies, Inc., a life sciences company focused on adult stem cell-based therapies for various personal medical applications, today announced that it has entered into a Research and Development Agreement with Rohto Pharmaceutical Company, Ltd. Under the Agreement, BRT has been engaged to provide stem cell research and development services.

25 Mar 2014

SIFI, NovaMedica agree to market eight products for treatment of ophthalmic pathologies in Russia

Leading Italian developer of innovative eye care solutions S.I.F.I. S.p.A. and Russian pharmaceutical company NovaMedica have entered into an exclusive commercial agreement for NovaMedica to market eight products developed and licensed by SIFI for the treatment of a wide range of ophthalmic pathologies in Russia and the CIS.

25 Mar 2014

LGL Group's total revenues for Q4 2013 decrease 6.6% to $5.7 million

The LGL Group, Inc., announced results for the full year and quarter ended December 31, 2013.

25 Mar 2014

Vigilant announces completion of $2 million oversubscribed Series A financing

Vigilant Biosciences, Inc., developer of the "rinse and spit" test for assessing early risk of oral cancer, today announced the successful completion of a $2.0 million, oversubscribed Series A financing. The company received $2.3 million in total proceeds, including a $300,000 loan from the Florida Institute for the Commercialization of Public Research Seed Capital Acceleration Program.

25 Mar 2014

BIND Therapeutics reports revenue of $2.1 million for fourth quarter 2013

BIND Therapeutics, Inc., a clinical-stage nanomedicine platform company developing targeted and programmable therapeutics called AccurinsTM, today reported financial results for the fourth quarter and year-ended December 31, 2013.

25 Mar 2014

PatientPoint signs distribution agreement with HealthTronics IT Solutions for urology technology

PatientPoint announced today that they have entered into a distribution agreement with HealthTronics IT Solutions to deliver population health management solutions within urology to drive improved adherence and compliance.

25 Mar 2014

Precision for Medicine announces acquisition of Hobart Group Holdings

Precision for Medicine, Inc., formed in 2012 to support next generation approaches to drug development and commercialization, announces the acquisition of Hobart Group Holdings, LLC, a leading market access firm. With this addition, Precision for Medicine has established the foundation for its next phase of growth in providing integrated solutions focused on demonstrating value in the era of precision medicine.

25 Mar 2014

Genable Technologies, Spark Therapeutics to advance novel therapy for rare form of retinitis pigmentosa

Spark Therapeutics and Genable Technologies announced today that they have entered into a collaboration agreement for Genable's lead therapeutic to treat rhodopsin-linked autosomal dominant retinitis pigmentosa (RHO adRP), GT038.

25 Mar 2014